• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Former Alcon executive becomes Iridex president/CEO

Article

Barry G. Caldwell joins Iridex Corp. as president and chief executive officer and as a member of the board of directors. He succeeds Theodore A. Boutacoff, who has been elected chairman of the board for Iridex.

Caldwell worked for Alcon Laboratories for more than 2 decades in numerous executive positions, including vice president of Alcon Canada as well as vice president and general manager of Alcon’s U.S. Surgical Division.

“His successful track record includes achievements in operating performance, strategic planning, mergers and acquisitions, and executing strategic initiatives-which resulted in profitable revenue growth,” Boutacoff said.

“With more than 30 years of experience in the ophthalmic sector and more than 20 years of tenure at Alcon, Barry has well-established relationships with physicians, industry executives, and key regulatory and legislative opinion leaders that will be beneficial to Iridex,” Boutacoff added.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.